HighGravityDataBioMarin Pharmaceutical — Oct 29, 2024 release
Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-24-000149
Showing in the filing
Total Revenues
“$2,790 to $2,825”
Period
FY2024
Measure
GAAP-tied
Source
Prose
All guidance in this release · 12
VOXZOGO country access expansion for FY2027
“more than 20 additional countries”
Total Revenues for FY2027
“Approximately $4 billion”
Non-GAAP Operating Margin for FY2026
“40%”
Non-GAAP Operating Margin
“low- to mid-40% range”
Operating cash flow for FY2027
“More than $1.25 billion”
Total revenues CAGR for FY2034
“Mid-teen compound annual growth rate (CAGR)”
Total revenues compound annual growth rate (… for FY2034
“Mid-teen”
Treatments for Skeletal Conditions revenue o…
“greater than $5 billion”
Total Revenues for FY2024
“$2,790 to $2,825”
Non-GAAP Operating Margin % for FY2024
“26.5% to 27.5%”
Non-GAAP Diluted EPS for FY2024
“$3.25 to $3.35”
Weighted-Average Diluted Shares Outstanding … for FY2024
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors. 2024 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated) Item Provided August 5, 2024 Updated October 29, 2024 Total Revenues $2,750 to $2,825 $2,790 to $2,825 Non-GAAP Operating Margin % (1) 26% to 27% 26.5% to 27.5% Non-GAAP Diluted EPS (1)(2) $3.10 to $3.25 $3.25 to $3.35 (1) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. (2) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss third quarter 2024 financial results today, Tuesday, October 29, 2024, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 888-596-4144 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-968-2525 Replay International Dial-in Number: 609-800-9909 Conference ID: 4980126 Conference ID: 4980126 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong cli
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.